Managing patients with late-onset neutropenia during treatment with ocrelizumab

Mult Scler. 2024 Jan;30(1):134. doi: 10.1177/13524585231206219. Epub 2023 Oct 27.

Authors

Sarah L Wright¹, Alan J Thompson²

Affiliations

¹ Department of Neurology, The National Hospital for Neurology and Neurosurgery, London, UK.
² Queens Square Institute of Neurology, UCL, London, UK.

PMID: 37888826
DOI: 10.1177/13524585231206219

No abstract available

MeSH terms

Antibodies, Monoclonal, Humanized / adverse effects
Humans
Immunologic Factors / adverse effects
Multiple Sclerosis* / chemically induced
Neutropenia* / chemically induced
Neutropenia* / drug therapy

Substances

ocrelizumab
Antibodies, Monoclonal, Humanized
Immunologic Factors